Future Fields utilizes its EntoEngine™ platform to produce custom recombinant proteins using fruit flies, enabling the scalable manufacturing of difficult-to-express proteins. This approach addresses the challenges of high production costs and environmental impact associated with traditional protein synthesis methods.
Funding
$14.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods of recombinant protein production often face challenges related to scalability, high costs, and environmental concerns, particularly when dealing with difficult-to-express proteins. These limitations can hinder research and development efforts across various industries.
Solution
Future Fields offers the EntoEngine™ platform, a novel biomanufacturing approach that leverages fruit flies for the production of custom recombinant proteins. This technology enables the scalable and cost-effective manufacturing of proteins that are traditionally difficult to express using conventional methods. By utilizing fruit flies as bioreactors, Future Fields provides a sustainable alternative to traditional protein synthesis, reducing both production costs and environmental impact. The platform aims to make previously unmakeable proteins accessible for a variety of applications.
Target Audience
The primary target audience includes researchers, biotech companies, and other organizations requiring access to high-quality, difficult-to-express recombinant proteins for various applications.
Features
- EntoEngine™ platform utilizing fruit flies as bioreactors for protein production
- Scalable manufacturing of difficult-to-express recombinant proteins
- Sustainable and cost-effective alternative to traditional protein synthesis methods
- Custom protein production services tailored to specific research and development needs